nominally significantP = 0.0420
There was a nominally significant benefit for GAD-alum treatment compared with placebo in lowering the increase in the standard deviation of blood glucose readings during the study period ( P = 0.0420 at 6 months, and P = 0.0219 at 15 months; Suppl Fig 1 ( 24 )), but there was no significant difference between the treatment arms regarding the coefficient of variation (standard deviation divided by the mean) measure of glycemic variability (Suppl Fig 2 ( 24 )).